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RESEARCH ARTICLE
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Abstract
Our objective was to identify whether rare genetic variation in amyotrophic lateral sclerosis (ALS) candidate survival genes
modifies ALS survival. Candidate genes were selected based on evidence for modifying ALS survival. Each tail of the
extreme 1.5% of survival was selected from the UK MND DNA Bank and all samples available underwent whole genome
sequencing. A replication set from the Netherlands was used for validation. Sequences of candidate survival genes were
extracted and variants passing quality control with a minor allele frequency 0.05 were selected for association testing.
Analysis was by burden testing using SKAT. Candidate survival genes UNC13A, KIFAP3, and EPHA4 were tested for
association in a UK sample comprising 25 short survivors and 25 long survivors. Results showed that only SNVs in
UNC13A were associated with survival (p ¼ 6.57 103). SNV rs10419420:G4A was found exclusively in long survivors
(3/25) and rs4808092:G4A exclusively in short survivors (4/25). These findings were not replicated in a Dutch sample. In
conclusion, population specific rare variants of UNC13A may modulate survival in ALS.
Keywords: ALS, survival, UNC13A, genetic modifiers, sequencing
Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegen-
erative disease predominantly of motor neurons,
resulting inprogressiveweaknessofvoluntarymuscles
and death from respiratory failure due to diaphrag-
matic paralysis, typically within three years of onset.
There is a strong genetic contribution to ALS
risk. Approximately 5% to 20% of cases have a family
history of ALS or frontotemporal dementia; the
remaining cases are sporadic, having no known
family history. Even in apparently sporadic cases,
twin and population studies estimate the heritability
to be about 60% (2). Genes for ALS have now been
identified in about 70% of those with a family history
and 15% of those without. Surprisingly, risk genes do
not strongly predict phenotype in most cases, with
only a few having any reliable relationship with prog-
nosis. For example, homozygosity for the p.D91A
mutation of SOD1 is associated with slowly progres-
sive ALS, and the p.A5V mutation of SOD1 with
rapid disease, but such a relationship is unusual.
Despite the very poor prognosis, there is consid-
erable variation in survival rate: up to 10% of people
with ALS live more than eight years from first
symptoms (3). A number of common gene variants
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associated with ALS survival have been identified
through genome-wide association studies and
animal models. These include variants in
UNC13A, EPHA4, and KIFAP3 (4–7).
The UNC13A association with survival has
been replicated, but the KIFAP3 finding has
failed to replicate in follow-up analyses (8,9).
The association of EPHA4 variants with survival
used a combination of functional and genetic
approaches but has not been found in genetic
association studies alone. Variants that confer
robust associations to survival may offer important
future therapeutic targets because patients present
after symptom onset and ALS is rare, making
primary prevention unfeasible (10). Survival genes
could potentially be targeted directly, or their
product augmented to improve ALS survival.
Genetic variation in survival genes could also be
used to predict prognosis and to help forecast
response to future therapeutic interventions, both
of which would be valuable in counselling patients
and for clinical trial design (11).
It remains to be seen if large-scale sequencing
studies identify rare variants in additional genes
which might also modify survival. Rare genetic
variation is either rare because it is recent in
evolutionary terms or because it generates a dele-
terious phenotype and is therefore selected against.
As a result, harmful rare variants might be enriched
in a phenotypically extreme sample (12) and may
have gone undetected in genetic association studies
to date, which have focused primarily on common
variation. We therefore searched for rare genetic
variation in candidate survival genes in individuals
showing extreme survival phenotypes in ALS, with
either very short survival or very long survival.
Materials and methodsCandidate survival gene
selection
Survival genes of interest were identified by litera-
ture review. MEDLINE and EMBASE were
searched in June 2015 using the key words ‘amyo-
trophic lateral sclerosis’ OR ‘ALS’ OR ‘motor
neuron disease’ OR ‘MND’ AND ‘survival’ AND
‘gene’. Further papers were identified by discussion
with known research groups. Any gene was included
if variants in or near the gene were identified as
associated with ALS survival in whole-genome
analysis. Studies analysing candidate genes or a
restricted subset of the genome were excluded.
Ethics
Informed consent was obtained from all subjects
included in the study. The study was approved by
the Trent Research Ethics Committee 08/H0405/60
and by the Medical Ethics Review Board at the
University Medical Centre Utrecht 05_067/E.
Patients were identified from the UK National
DNA Bank for Motor Neuron Disease Research
(MND DNA bank) and King’s MND DNA bank.
Survival was measured from symptom onset and
information collected by follow-up of patients until
death or last clinic visit. Informed written consent
was obtained from all participants for participation
in genetic research.
Samples
The top and bottom 1.5% of ALS patients by survival
were identified (25 patients from each tail of the
distribution). All patients were classified as definite
or probable ALS according to the El Escorial criteria
and had no family history of ALS. Sample ancestry
and relatedness were evaluated by principal compo-
nents analysis and relationship matrices.
Procedures
Whole-genome sequencing was performed by
Illumina (San Diego, CA, USA) using the
HiSeq2000 platform. All sample data were pro-
cessed with the Illumina Whole Human Genome
Sequencing Informatics Pipeline. High-quality
sequence reads were aligned using the iSAAC
Sequence Aligner And Counter and variant calling
was performed using the iSAAC Variant Caller.
Quality control measures were applied to single
nucleotide variation (SNV) data. SNVs were
excluded from analysis using the following quality
control parameters: if the locus had heterozygous
genotype in a haploid region, read depth was greater
than 3x the mean chromosome read depth; the
fraction of base calls filtered out at a site was40.3
SNV contextual homopolymer; length exceeded 6;
SNV strand bias value exceeded 10; or genotype
quality assuming variant position was530.
Replication studies
For replication, a second set of samples from the
Netherlands was studied. Samples were whole-
genome sequenced on the Illumina HiSeq 2000
platform and underwent alignment and variant
calling identical to that performed in the UK
samples. Samples were cleaned based on depth of
coverage, Ti/Tv ratio, missingness, relatedness,
ancestry evaluated by principal component analysis,
a gender check (to identify mismatches), inbreeding,
and genotyping-sequence concordance (made pos-
sible by genotyping data generated on the Omni
2.5M for all samples). After QC, short-term sur-
vivors (n ¼ 368) who lived at most two years from
symptom onset and long-term survivors (n ¼ 91)
who lived at least six years after symptom onset were
selected for association testing.Statistical analysis
For discovery, patients were dichotomised into short
survival and long survival groups, and analysed by
group. For genes meeting criteria for inclusion as
candidate survival genes, genotype data on variants
lying within genes was extracted, including introns
and 500bp upstream and downstream. A gene-
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based SKAT test (13) was conducted to compare
burden of rare variation in the two groups. SKAT
analysis was conducted in Variant Tools (14) and
Variant Association Tools (15) by implementation of
the R package ‘SKAT’ (http://cran.r-project.org/
web/packages/SKAT/). This implementation of
SKAT generates empirical p-values and uses meth-
ods for small sample size adjustment (13). Variants
with minor allele frequency (MAF)  0.05 in this
dataset were included in the SKAT burden analysis
in keeping with previous extreme phenotype studies
(16). Bonferroni correction for the number of genes
tested was used to account for multiple testing.
To allow covariate analysis with the common
variant rs12608932:A4C in UNC13A previously
associated with ALS and with ALS survival, this
variant was genotyped using Illumina 2.5M bead-
chip microarrays, performed at the same time as
sequencing.
Identification of rare individual SNVs driving the
SKAT analysis result was conducted with PLINK/
SEQ software version 0.1 (https://atgu.mgh.harvar-
d.edu/plinkseq). Haploview was used to analyse
linkage disequilibrium between SNPs (17). SNAP
(https://www.broadinstitute.org/mpg/snap/) was
used to identify long-range linkage disequilibrium.
To estimate population frequencies of variants,
we used the 503 European ancestry samples from
the 1000 Genomes dataset.
Results
Literature review identified 761 papers referring to
ALS survival genes. Three genes passed our inclu-
sion criteria: UNC13A, identified from genome-
wide association studies; EPHA4, identified by a
genome-wide morpholino-based zebrafish knock-
down screen followed by testing in humans; and
KIFAP3, identified in a genome-wide association
study, although not subsequently confirmed as a
survival gene in other studies (5–9).
The short and long survivors were of the same
ancestry as the general UK ALS population as
shown by principal components analysis
(Supplementary Figure 1). There was no cryptic
relatedness (pi-hat 50.05 in all pairwise compari-
sons). Short survivors lived at most 1.5 years from
symptom onset, and long survivors at least six years.
Demographic details for the study groups are shown
in Table I. The Kaplan–Meier survival curve for the
population from which the study groups were
derived is shown in Figure 1. The median survival
for this population is 2.76 years.
There were 16 rare variants passing quality
control with MAF 0.05. Using burden testing as
implemented in SKAT, we did not find association
with survival of rare variants in KIFAP3 (p¼ 1.0; six
variants) or EPHA4 (p¼ 0.49; two variants). SNVs
in UNC13A were associated with survival (p¼ 6.57
 103; eight variants) passing the Bonferroni
corrected significance threshold of 0.017 (0.05/3).
Extending the analysis to include all variants
with a frequency cut-off of MAF 0.125 did not
change the results.
Analysis of the rare variation within UNC13A
driving the association, revealed three intronic
SNVs, rs7260188:G4T, rs10419420:G4A and
rs4808092:G4A (Figure 2). Minor alleles at
SNVs rs7260188 and rs10419420 occurred only in
the long survival group, in two and three individuals,
respectively, and were in linkage disequilibrium
(r2¼ 0.66) (Figure 2, Table II). SNV
rs4808092:G4A was carried by four individuals in
the short survival group only (Table IV).
Because a possible explanation for the associ-
ation is linkage disequilibrium with the common
variant rs12608932, A4C known to be associated
with ALS survival (4,6), we examined the haplotypic
and correlation structure of the rare and common
variants together (Figure 2, Table II) and compared
frequencies with results from the 1000 Genomes
Project (Table III). We also repeated the SKAT
analysis of UNC13A using the presence of the
common variant rs12608932, A4C as a covariate
Figure 1. Kaplan–Meier survival curve for the whole population
from which the study groups were derived.
Table I. Demographic features of the long and short survival
groups (UK cohort).
Long survival
group
Short
survival
group
Number 25 25
Male:Female 10: 15 8: 17
Mean age of onset (y) 53.7 60.2
Proportion alive 0.6 0.04
Median survival (KM method) (y) 9.16 1.04
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which did not affect the results (p¼ 0.01). The
rs7260188 SNV is monomorphic in 1000 Genomes
EUR data. The findings support a difference in
allele frequencies between ALS cases and 1000
Genomes controls. Similarly, there is a difference in
allele frequency for the common SNV, rs12608932
with the C allele present in 55% of ALS chromo-
somes and 35% of 1000 Genomes EUR chromo-
somes, consistent with existing association studies of
this SNV.
To replicate the findings, we studied a dataset
from the Netherlands that had been selected,
processed and sequenced in an almost identical
way. There was no significant difference in allele
frequencies between the long and short survivors,
and SKAT analysis of rare variation in UNC13A
Figure 2. Visual representation of location of rare and common SNVs within UNC13A and associated LD plot. Intron/exon status and
number of individuals in long/short survival groups given for rare SNVs.
Table IV. Genotype count data for variants of interest in UK
discovery cohort.
Frequency in UK discovery cohort
SNV Genotypes
Long survival
group (n¼25)
Short survival
group (n¼ 25)
rs7260188 G G 23 25
G t 2 0
tt 0 0
rs10419420 G G 21 25
G a 3 0
aa 0 0
rs12608932 A A 3 3
A c 18 15
cc 4 7
rs4808092 G G 25 21
G a 0 4
aa 0 0
Table II. Linkage disequilibrium values for SNPs in UNC13A
associated with extremes of survival in a UK population.
D0 R2
rs7260188 rs10419420 1 0.66
rs7260188 rs12608932 1 0
rs7260188 rs4808092 1 0.001
rs10419420 rs12608932 1 0.016
rs10419420 rs4808092 1 0.001
rs12608932 rs4808092 0.139 0.001
Table III. SNV minor allele frequency (MAF) for UK study
population and 1000 Genomes Project.
Minor allele frequency (MAF)
SNV
UK study
population
1000 Genomes
Project
rs7260188 0.020 0.0
rs10419420 0.031 0.005
rs12608932 0.450 0.349
rs4808092 0.040 0.046
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revealed no significant difference between the long
and short survival groups (p¼ 0.132; 271 variants).
Surprisingly, SNV rs10419420 shows strong
long range linkage disequilibrium in 1000
Genomes CEU data with rs77902754, 4400Kb
distant (r2¼ 0.99, Figure 3). This finding was not
replicated in the Dutch dataset.
Discussion
We have shown that rare variation in the UNC13A
gene may modify survival in ALS in a UK sample
set, but this is not replicated in a second sample set
from the Netherlands. The association is independ-
ent from that of common variation at rs12608932,
which is associated with ALS risk and survival
(4,6,18). We have not found rare SNVs modifying
ALS risk in the EPHA4 or KIFAP3 genes.
The rare variants identified in UNC13A in the
UK sample were intronic and exclusively found in
one or other extreme of survival. SNV rs10419420
variation was only seen in the long survivors, and
rs4808092 variation only seen in the short survivors.
The allele frequencies of the UK sample and
population estimates from the 1000 Genomes
EUR samples [www.1000genomes.org] are given
in Table III. Seven of 50 individuals (14%) in this
study carried one of the survival modifying variants.
There are a few possible explanations for the lack
of replication of the finding. First, it is possible that
the UK results represent a false-positive association.
Secondly, rare variants are more likely to be popu-
lation-specific than common variants, and it is
therefore more likely that rare variation within a
gene modifying survival varies by population,
accounting for the differences identified between
the populations sampled in this study. Of the three
variants identified in the UK samples, one was
monomorphic in the Dutch samples, and the other
two had a minor allele frequency45% and were not
therefore rare.
Overall, population-specific effects are likely to
represent a significant challenge affecting whole
genome sequencing studies focusing on rare vari-
ation because the large population samples that may
be required to replicate findings within different
geographical cohorts will be extremely challenging
to collect in relatively rare diseases. This is fur-
ther compounded by the unknown significance of
intronic variation and other ‘non-functional’ vari-
ation identified with whole-genome sequencing
designs.
The common rs12608932 SNV in UNC13A has
been identified as both an ALS risk (19,20) and
survival (6,18) variant. This study adds to the body
of evidence supporting UNC13A variants as import-
ant in modifying ALS survival and suggests that the
pathological effect may not be confined to a function
of rs12608932 or an associated variant.
The mechanistic role of UNC13A in ALS
survival remains unclear, although it is known to
play a role in neurotransmission. The mouse
Figure 3. Long-range LD plot of UNC13A SNV rs10419420. The position of the KCNN1 gene, for which the common rs12608932 SNV
in UNC13A acts as an eQTL, is shown with an arrow. Generated using SNPAnnotation and Proxy Search (www.broadinstitute.org/mpg/
snap/ldplot.php).
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homolog of the UNC13A protein, Munc13, has
been shown to play a role in neurotransmission with
a central role in synaptic-vesicle priming (21).
Munc13 deficiency has been shown to influence
glucose homeostasis resulting in abnormal glucose
tolerance (22). A number of studies have identified
abnormal glucose metabolism in patients with ALS
and a primary metabolic abnormality in ALS has
been proposed (23,24). A study of a C. elegans
model of ALS has shown that unc-13, the C. elegans
homolog of UNC13A, plays a role in motor neuron
degeneration through interaction with TDP-43, a
key pathological protein in ALS (25,26). Thus, at
least three potential mechanisms link UNC13A with
motor neuron degeneration, and all could either
increase ALS risk or affect the rate of neurodegen-
eration and, therefore, survival.
The rarer SNV associated with long survival,
rs7260188 and the more common SNP
rs10419420, are in strong linkage disequilibrium.
SNV rs7260188 is monomorphic in 1000 Genomes
EUR samples, and is only found in two of the three
patients with the rs10419420 SNV; we have there-
fore focused analysis on rs10419420.
The linkage disequilibrium pattern of the three
main variants, rs10419420 found in the long sur-
vivors, the common SNV rs12608932, and
rs4808092, found in the short survivors is complex.
The r2 relationships are all close to zero, both in this
study and in public data. This is expected since a
common variant will often have low r2 with a rare
variant, because the allele frequencies are different.
For the rare variants, the low r2 arises because the
minor allele at rs10419420 lies on the common allele
at rs4808092. The genotypes at any one locus are
therefore independent of those at the others.
Similarly, in both this study and the public data, the
D’ and haplotype patterns show that for the rare
SNVs, each rare allele lies on the common allele at
the other marker (Table III) and there is no evidence
for the fourth haplotype (both rare alleles).
However, when the common SNV is included, the
rs10419420 SNV, associated with long survival, is
only seen on the common allele of the common SNV,
while the rs4808092 SNV, associated with short
survival, is seen on either haplotype. This means that
there is a haplotype seen in the long survivors, AAG
(2.5%), that is not seen at all in the 1000 Genomes
data.
The SNV associated with long survival,
rs10419420, is in very strong long-range LD with
SNV rs77902754 (Figure 2, r2¼ 0.99). The
rs77902754 SNV lies in a regulatory region compris-
ing a transcription binding site, transcribed mRNAs
and an H3K27Ac mark, and is very close to the
KCNN1 gene, a calcium activated potassium chan-
nel which contributes to neuronal excitability. This
proximity is important because the common
rs12608932 SNV in UNC13A has been proposed to
act as an expression quantitative trait locus
(eQTL) for KCNN1 (27,28). Thus there are two
independent signals relating variation in the
UNC13A gene to the region around KCNN1, and
although SKATanalysis does not directly identify an
association between rare variants in KCNN1 and
survival (p¼ 0.579), it remains possible that the
signal seen inUNC13A is a proxy for biological effects
conferred by KCNN1 or a different protein.
A weakness of this study is the small sample size
limiting the statistical power of the study. We have
attempted to mitigate this by selecting samples on
the basis of extreme phenotype, which is known to
increase power (12). We have also restricted the
study only to candidate survival genes despite having
whole-genome sequence data, thus reducing the
multiple testing burden. We have used a SKAT
burden test, which improves power to detect asso-
ciation for rare variant studies because it allows
detection of protective and deleterious alleles at the
same locus. A strength of the study is the detailed
sequencing of the candidate genes, allowing detec-
tion of all rare and common variation.
Our study highlights the potential for extreme
phenotype design in the search for survival genes
and rare variants associated with ALS.
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